Biological Activity
Usp22i-S02(USP22-IN-1, compound S02) is a potent inhibitor of ubiquitin specific peptidase 22 (USP22). It showed anticancer activity by suppressing Foxp3 expression in T-regulatory cells.
In Vitro
USP22-IN-1 (compound S02) reduces the expression of Foxp3 MFI and cell viability in a dose-dependent manner at concentrations of 0, 5, 10, 15, 20, and 25 µg/mL [1]. At a concentration of 10 µg/mL and during an incubation time of 0-12 hours, USP22-IN-1 decreases the expression levels of FOXP3, USP22 protein, and Foxp3 mRNA in iTreg cells [1]. The Cell Viability Assay showed that cell survival was inhibited in a dose-dependent manner [1]. Western Blot Analysis revealed that the expression of FOXP3 and USP22 decreased in a time-dependent manner when cells were treated with 10 µg/mL of USP22-IN-1 [1].
In Vivo
USP22-IN-1 (20 mg/kg; i.p.; twice a day for 5 days) enhances the anti-tumor immunity in mice [1]. The study used male C57BL/6 mice (6-8 weeks old) with LLC1 cells [1]. The dosage administered was 20 mg/kg via intraperitoneal injection, given twice a day for 5 days [1]. The results showed an improvement in anti-tumor immunity, leading to decreased tumor cell counts, reduced viability, and inhibited tumor growth [1].
Target
USP22[1]
References & source
[1]. Deyu FANG, et al. Inhibitors of ubiquitin specific peptidase 22 (usp22) and uses thereof for treating diseases and disorders. WO2022226402A1.
Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.
